This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (81)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Neurology  • Alzheimer Disease  • Dementias  • Psychopharmacology  • Alert me on articles by topic  Social Bookmarking   What's this?

The Cache County Study

Peter P. Zandi, PhD; D. Larry Sparks, PhD; Ara S. Khachaturian, PhD; JoAnn Tschanz, PhD; Maria Norton, PhD; Martin Steinberg, MD; Kathleen A. Welsh-Bohmer, PhD; John C. S. Breitner, MD; for the Cache County Study Investigators

Arch Gen Psychiatry. 2005;62:217-224.

Background  Prior reports suggest reduced occurrence of dementia and Alzheimer disease (AD) in statin users, but, to our knowledge, no prospective studies relate statin use and dementia incidence.

Objective  To examine the association of statin use with both prevalence and incidence of dementia and AD.

Design  Cross-sectional studies of prevalence and incidence and a prospective study of incidence of dementia and AD among 5092 elderly residents (aged 65 years or older) of a single county. Participants were assessed at home in 1995-1997 and again in 1998-2000. A detailed visual inventory of medicines, including statins and other lipid-lowering agents, was collected at both assessments.

Main Outcome Measures  Diagnosis of dementia and of AD.

Results  From 4895 participants with data sufficient to determine cognitive status, we identified 355 cases of prevalent dementia (200 with AD) at initial assessment. Statin use was inversely associated with prevalence of dementia (adjusted odds ratio, 0.44; 95% confidence interval, 0.17-0.94). Three years later, we identified 185 cases of incident dementia (104 with AD) among 3308 survivors at risk. Statin use at baseline did not predict incidence of dementia or AD (adjusted hazard ratio for dementia, 1.19; 95% confidence interval, 0.53-2.34; adjusted hazard ratio for AD, 1.19; 95% confidence interval, 0.35-2.96), nor did statin use at follow-up (adjusted odds ratio for dementia, 1.04; 95% confidence interval, 0.56-1.81; adjusted odds ratio for AD, 0.85; 95% confidence interval, 0.32-1.88).

Conclusions  Although statin use might be less frequent in those with prevalent dementia, we found no association between statin use and subsequent onset of dementia or AD. Further research is warranted before costly dementia prevention trials with statins are undertaken.

Author Affiliations: Department of Mental Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Md (Drs Zandi and Khachaturian); SunHealth Research Institute, Sun City, Ariz (Dr Sparks); Department of Psychology and the Center for Epidemiologic Studies (Drs Tschanz and Norton), Department of Family and Human Development (Dr Norton), Utah State University, Logan; Department of Psychiatry, School of Medicine, Johns Hopkins University, Baltimore (Dr Steinberg); Department of Psychiatry and Behavioral Sciences and the Joseph and Kathleen Bryan Alzheimer’s Disease Research Center, Duke University Medical Center, Durham, NC (Dr Welsh-Bohmer); VA Puget Sound Health Care System and the Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle (Dr Breitner).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Preventing dementia: role of vascular risk factors and cerebral emboli
Purandare
Br Med Bull 2009;0:ldp020v1-ldp020.
ABSTRACT | FULL TEXT  

Statins and cognitive function
Sparks
J. Neurol. Neurosurg. Psychiatry 2009;80:1-2.
FULL TEXT  

Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study
Haag et al.
J. Neurol. Neurosurg. Psychiatry 2009;80:13-17.
ABSTRACT | FULL TEXT  

The Role of Statin Drugs in the Management of the Peripheral Vascular Patient
Samson
VASC ENDOVASCULAR SURG 2008;42:352-366.
ABSTRACT  

Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study
Cramer et al.
Neurology 2008;71:344-350.
ABSTRACT | FULL TEXT  

Statins, incident Alzheimer disease, change in cognitive function, and neuropathology
Arvanitakis et al.
Neurology 2008;70:1795-1802.
ABSTRACT | FULL TEXT  

Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease
Patterson et al.
CMAJ 2008;178:548-556.
ABSTRACT | FULL TEXT  

Association of statin use with cognitive decline in elderly African Americans
Szwast et al.
Neurology 2007;69:1873-1880.
ABSTRACT | FULL TEXT  

Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease
Li et al.
Neurology 2007;69:878-885.
ABSTRACT | FULL TEXT  

Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology
Burns and O'Brien
J Psychopharmacol 2006;20:732-755.
ABSTRACT  

High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels.
Thelen et al.
J Clin Pharmacol 2006;46:812-816.
ABSTRACT | FULL TEXT  

Lipid lowering agents to delay cognitive decline in Alzheimer's disease?
de Leeuw
J. Neurol. Neurosurg. Psychiatry 2005;76:1611-1613.
FULL TEXT  

Combination Pharmacotherapy for Cardiovascular Disease
Combination Pharmacotherapy and Public Health Rese
ANN INTERN MED 2005;143:593-599.
ABSTRACT | FULL TEXT  

Serum cholesterol and risk of Alzheimer disease: A community-based cohort study
Li et al.
Neurology 2005;65:1045-1050.
ABSTRACT | FULL TEXT  

Do Statins Reduce Risk for Dementia?
JWatch Psychiatry 2005;2005:7-7.
FULL TEXT  

Do Statins Reduce Risk for Dementia?
Journal Watch Cardiology 2005;2005:5-5.
FULL TEXT  

Do Statins Reduce Risk for Dementia?
JWatch General 2005;2005:1-1.
FULL TEXT